Why Is INSMED INC (INSM) Stock Up Today?

Insmed shares surged 14.00% to $110.56 following the release of third-quarter financial results. The primary driver was a significant revenue beat and an upward revision to full-year sales guidance, which offset a miss in earnings per share.

What Happened

Insmed reported third-quarter revenue of $524.4 million, exceeding estimates by $24.92 million. While GAAP EPS of -$0.46 missed the consensus estimate of -$0.38 by $0.08, the company highlighted strong growth in its BRINSUPRI and ARIKAYCE products. Management raised fiscal year 2026 sales guidance from a range of $1.700 billion to $1.870 billion to a new range of $1.810 billion to $1.870 billion. This update was disclosed via an 8-K filing on October 29, 2026, accompanied by an earnings call presentation.

What The Data Shows

The stock opened at $98.84, representing a 1.9% gap from the prior close of $96.98. Trading volume reached 2.3 million shares, which is 0.8 times the three-month daily average. The session high hit $118.00 at 7:15 AM ET, while the low was $98.80 at 7:00 AM ET. Insmed has a market cap of $20.7 billion and remains unprofitable with a trailing twelve-month EPS of -4.09. Revenue growth stands at 185.8% over the same period, though the net margin is -76.9%. The stock has a beta of 0.82 and a 52-week range of $90.39 to $212.75. Over the last 8 sessions, the stock moved up 1.8% from $95.29 to $96.98. Recent insider activity includes four sales totaling $39.2 million in the last 90 days, with the most recent filing on September 11, 2026.

What To Watch

Investors will monitor how the raised guidance impacts future valuation metrics, particularly given the company's price-to-sales ratio. The stock printed three fresh 52-week highs and two fresh 52-week lows on October 29, 2026, indicating high volatility around the earnings release.